Razlog je jednostavan, a naveli smo ga vie puta u ovom tekstu lek Retatrutid i dalje nije zvanino odobren za upotrebu, niti je puten u promet bilo gde na svetu
Zepbound is an FDA-approved, once-weekly injectable GLP-1 medication for chronic weight management, authorized in October 2023
Choosing the right method is key for treating B12 deficiency
Its role in obesity treatment remains marginal-under 1% -but adoption is rising through clinical integrations and bundling with telehealth-based interventions targeting metabolic and appetite-related outcomes
Anyone with existing swelling who is considering one of these medications should have the cause of the swelling worked up first, because starting an appetite-reducing drug does nothing to diagnose heart, liver or kidney disease and may delay finding it
Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes [published online March 29, 2025]